Leerink Partnrs Reiterates “Outperform” Rating for LENZ Therapeutics (NASDAQ:LENZ)

LENZ Therapeutics (NASDAQ:LENZ)‘s stock had its “outperform” rating reaffirmed by investment analysts at Leerink Partnrs in a research report issued on Monday, Zacks.com reports. Leerink Partnrs also issued estimates for LENZ Therapeutics’ Q1 2024 earnings at ($0.51) EPS, Q2 2024 earnings at ($0.47) EPS, Q3 2024 earnings at ($0.40) EPS, Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.80) EPS, FY2025 earnings at ($2.20) EPS, FY2026 earnings at ($1.30) EPS, FY2027 earnings at $0.85 EPS and FY2028 earnings at $2.70 EPS.

Other equities research analysts have also issued research reports about the stock. Piper Sandler started coverage on shares of LENZ Therapeutics in a report on Wednesday, March 27th. They set an “overweight” rating and a $28.00 price target on the stock. SVB Leerink assumed coverage on shares of LENZ Therapeutics in a report on Monday. They set an “outperform” rating and a $32.00 price target on the stock. Citigroup assumed coverage on shares of LENZ Therapeutics in a research note on Wednesday, April 10th. They issued a “buy” rating and a $34.00 price objective on the stock. Finally, William Blair assumed coverage on shares of LENZ Therapeutics in a research note on Monday. They issued an “outperform” rating on the stock. Five equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $31.33.

LENZ Therapeutics Price Performance

Shares of NASDAQ LENZ traded down $2.22 during midday trading on Monday, reaching $17.70. The company’s stock had a trading volume of 84,141 shares, compared to its average volume of 58,430. LENZ Therapeutics has a one year low of $14.07 and a one year high of $29.82. The company has a market capitalization of $147.26 million, a P/E ratio of -1.13 and a beta of 0.20.

Insider Buying and Selling at LENZ Therapeutics

In other LENZ Therapeutics news, Director Ra Capital Management, L.P. acquired 998,009 shares of the company’s stock in a transaction dated Thursday, March 21st. The stock was bought at an average price of $15.03 per share, for a total transaction of $15,000,075.27. Following the purchase, the director now owns 3,319,339 shares in the company, valued at approximately $49,889,665.17. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 38.40% of the company’s stock.

LENZ Therapeutics Company Profile

LENZ Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing aceclidine-based eye drop to enhance vision in patients diagnosed with presbyopia. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.